Positive Phase III Results May Mean Big Payday for Ariad
Top-line results from a Phase III trial showed that Ariad Pharmaceuticals Inc.'s ridaforolimus has promise as a treatment for metastatic soft-tissue or bone sarcoma. In the trial designated SUCCEED, carried out under a special protocol assessment granted by the FDA, there was a 28 percent reduction in the risk of progression compared to placebo, and a 21 percent (or 3.1 week) improvement in progression-free survival.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST